Roivant Sciences has co-led a $40.5m round for Datavant, an offshoot it launched in August following a $1.1bn round led by SoftBank Vision Fund.
Datavant, a US-based healthcare data services subsidiary of drug developer Roivant Sciences, closed a $40.5m funding round on Monday co-led by Roivant with Datavant’s co-founder and CEO, Travis May.
The investment was announced concurrently with Datavant’s acquisition of Universal Patient Key (UPK), a provider of de-identification services for healthcare data. Financial terms of that deal were not disclosed.
Datavant, launched in August 2017, has developed a platform that enables the secure linking of separate healthcare datasets to better conduct…
